Sutro Biopharma STRO Accrued Progress Collections and Price Adjustments
Accrued Progress Collections and Price Adjustments at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's accrued progress collections and price adjustments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's accrued progress collections and price adjustments?
- Sutro Biopharma (STRO) reported accrued progress collections and price adjustments of $1.23M in Q1 2026.
- How has Sutro Biopharma's accrued progress collections and price adjustments changed year-over-year?
- Sutro Biopharma's accrued progress collections and price adjustments decreased by 85.6% year-over-year, from $8.57M to $1.23M.
- What is the long-term trend for Sutro Biopharma's accrued progress collections and price adjustments?
- Over 4 years (2020 to 2025), Sutro Biopharma's accrued progress collections and price adjustments has grown at a -24.1% compound annual growth rate (CAGR), from $6.1M to $2.03M.